Thursday, October 15, 2026

Abaxx Exchange Fights Viceroy Short Report, Posts Record June Trading Volume

Abaxx Technologies is countering a short-and-distort report from Viceroy Research with a multi-front defense: outside counsel Paul Weiss, direct outreach to regulators MAS and CIRO, and public rebuttals. The pushback lands alongside Abaxx Exchange's best trading month on record in June 2026.

LM Salvado
LM Salvado

July 12, 2026

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
Abaxx Exchange Fights Viceroy Short Report, Posts Record June Trading Volume
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Abaxx Technologies is fighting back against a short-seller report with lawyers, regulators, and trading data.1 Viceroy Research published a report alleging misconduct at Abaxx, a move the company calls a short-and-distort attack designed to push the stock down for profit.1

Abaxx retained law firm Paul Weiss to investigate Viceroy's claims.1 The company also engaged two regulators directly: Singapore's Monetary Authority (MAS) and Canada's CIRO.1 The CIRO outreach goes further than a standard rebuttal — Abaxx asked the regulator to examine Viceroy's own trading activity around the report's release.1 That request shifts scrutiny onto the short-seller itself, a tactic companies increasingly use when they suspect a report was timed to profit from a stock drop.1

Abaxx has publicly labeled the Viceroy report misinformation.1 The company is pairing that message with operational proof: Abaxx Exchange posted its best trading month on record in June 2026.1 Record volume during the same window as the attack undercuts Viceroy's narrative with hard numbers rather than just denials.1

The dispute touches both securities and regulatory domains, and market sentiment on Abaxx has been mixed but improving since the report emerged.1 The playbook here — outside counsel, dual regulatory engagement, and public data releases — mirrors how other exchanges and issuers have responded to short-seller campaigns in past years, though Abaxx's move to trigger a regulatory probe into the short-seller's own trading is a more aggressive counter than most companies attempt.

For investors, the case underscores a broader dynamic in markets: short-and-distort reports can move share prices quickly, but companies with strong underlying operating data have more room to fight back credibly. Abaxx's record trading volume gives its rebuttal a concrete data point that a written denial alone would lack.

Regulators at MAS and CIRO have not yet issued findings on either the original allegations or Abaxx's counter-complaint about Viceroy's trading. The outcome of those reviews will determine whether Abaxx's defense holds or whether Viceroy's claims gain traction.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· June 22, 2026
    Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals
  2. [2]Press releaseGlobeNewswire· June 30, 2026
    Raytech Holding Limited Announces Closing of Approximately $6.2 Million Registered Direct Offering of its Ordinary Shares
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com